Pfizer/Meridian win $60m BARDA contract for nerve agent countermeasure
This article was originally published in Scrip
Executive Summary
Pfizer subsidiary Meridian Medical Technologies won a five-year contract worth up to $60m from the US Biomedical Advanced Research and Development Authority (BARDA) to support development of midazolam delivered by a prefilled, pen-like autoinjector as a medical countermeasure (MCM) against nerve agent exposure.